NEW YORK, December 31, 2025, 14:50 ET — Regular session
- Alignment Healthcare shares rose about 3.4% in mid-afternoon trading.
- SEC filings showed multiple executives sold stock tied to tax withholding after awards vested.
- Traders are watching early-2026 utilization trends and the company’s next public update.
Alignment Healthcare, Inc. shares rose about 3.4% to $19.90 in mid-afternoon trading on Wednesday, after earlier touching $19.93 as the stock fluctuated between $18.83 and $19.93.
The move came as investors weighed a cluster of insider-transaction disclosures that can shape sentiment in smaller healthcare names, especially in thin year-end markets.
Liquidity has been patchy heading into the New Year holiday, a setup that can magnify price swings. “Profit-taking opportunities” tend to show up “when liquidity was low,” said Giuseppe Sette, co-founder and president of Reflexivity. Reuters
A Form 4 filing showed founder and Chief Executive John Kao sold 605,648 shares on Dec. 29 at weighted-average prices of $18.7056 and $19.3818, totaling about $11.35 million. The filing said the shares were sold to cover tax withholding tied to the vesting of performance share units.
Another Form 4 showed President Dawn Christine Maroney sold 282,070 shares in two transactions on the same day for about $5.29 million, with the filing also citing tax withholding tied to vesting awards.
Filings from Chief Legal and Administrative Officer Christopher Joyce, Chief Medical Officer Hyong Kim and Chief Information Officer Robert Scavo showed additional sales on Dec. 29 at similar prices. Joyce sold 16,187 shares, Kim sold 12,694 shares and Scavo sold 69,541 shares, the filings showed.
Form 4 is the SEC document companies’ insiders use to disclose buys and sells. Performance share units are stock awards that vest when performance targets are met, and vesting can trigger a tax bill even if the insider is not making a discretionary trade.
Alignment’s gains outpaced some larger managed-care names on Wednesday. UnitedHealth Group and Humana were down about 0.3% in afternoon trading, while Elevance Health rose about 0.6%.
Alignment sells Medicare Advantage plans, a privately run alternative to traditional Medicare, and investors typically track membership growth and medical costs as the plan year turns over. The company said in October that third-quarter revenue rose 43.5% to $993.7 million and membership climbed to about 229,600.
For traders, the filings land at a delicate moment: insider selling can look ominous after a run-up, but tax-driven sales often carry less signal than elective selling. The near-simultaneous timing across executives points to an award-vesting event rather than a coordinated view on valuation.
What investors are watching next is the fourth-quarter update on utilization trends and the medical loss ratio — a measure of how much premium revenue is spent on patient care. Any commentary on 2026 pricing, benefits and Medicare “star” ratings, which influence bonus payments, can move sentiment quickly.
The next scheduled company appearance is its presentation at the J.P. Morgan Healthcare Conference on Jan. 14, the company said. Investors will listen for any refreshed view on membership growth and margins after the first weeks of the 2026 plan year.
